Kissei purchase of MediciNova stock funds ex-Kissei asthma/COPD candidate
This article was originally published in Scrip
Executive Summary
MediciNova, which is traded on both the NASDAQ market and the Jasdaq market of the Osaka Securities Exchange, plans to raise $7.5 million to fund development of MN-221, its Phase II acute asthma drug. And it is doing it by selling stock to Japan’s Kissei Pharmaceutical, the company from which it licensed MN-221 in the first place.